Market Cap : 960.95 M | Enterprise Value : 864.14 M | PE Ratio : At Loss | PB Ratio : |
---|
NYSE:MYOV has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NYSE:MYOV has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Myovant Sciences's annualized Net Income for the quarter that ended in Mar. 2022 was $-237.1 Mil. Myovant Sciences's average total tangible assets for the quarter that ended in Mar. 2022 was $562.2 Mil. Therefore, Myovant Sciences's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2022 was -42.18%.
The historical rank and industry rank for Myovant Sciences's Return-on-Tangible-Asset or its related term are showing as below:
During the past 7 years, Myovant Sciences's highest Return-on-Tangible-Asset was -31.62%. The lowest was -207.23%. And the median was -77.77%.
MYOV's Return-on-Tangible-Asset is ranked better thanThe historical data trend for Myovant Sciences's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Myovant Sciences's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Myovant Sciences's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Myovant Sciences's Return-on-Tangible-Asset falls into.
Myovant Sciences's annualized Return-on-Tangible-Asset for the fiscal year that ended in Mar. 2022 is calculated as:
Return-on-Tangible-Asset | = | Net Income | / | ( (Total Tangible Assets | + | Total Tangible Assets) | / count ) |
(A: Mar. 2022 ) | (A: Mar. 2021 ) | (A: Mar. 2022 ) | |||||
= | Net Income | / | ( (Total Assets - Intangible Assets | + | Total Assets - Intangible Assets) | / count ) | |
(A: Mar. 2022 ) | (A: Mar. 2021 ) | (A: Mar. 2022 ) | |||||
= | -205.981 | / | ( (725.027 | + | 520.011) | / 2 ) | |
= | -205.981 | / | 622.519 | ||||
= | -33.09 % |
Myovant Sciences's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2022 is calculated as:
Return-on-Tangible-Asset | = | Net Income | / | ( (Total Tangible Assets | + | Total Tangible Assets) | / count ) |
(Q: Mar. 2022 ) | (Q: Dec. 2021 ) | (Q: Mar. 2022 ) | |||||
= | Net Income | / | ( (Total Assets - Intangible Assets | + | Total Assets - Intangible Assets) | / count ) | |
(Q: Mar. 2022 ) | (Q: Dec. 2021 ) | (Q: Mar. 2022 ) | |||||
= | -237.14 | / | ( (604.292 | + | 520.011) | / 2 ) | |
= | -237.14 | / | 562.1515 | ||||
= | -42.18 % |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Mar. 2022) net income data.
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companyÂ’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companyÂ’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Thank you for viewing the detailed overview of Myovant Sciences's Return-on-Tangible-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.
Potter Myrtle S | director | 10 FINDERNE AVE BRIDGEWATER NJ 08807 |
Guinan Mark | director | C/O QUEST DIAGNOSTICS 500 PLAZA DRIVE SECAUCUS NJ 07094 |
Arjona Ferreira Juan Camilo | officer: Chief Medical Officer | C/O MYOVANT SCIENCES INC. 2000 SIERRA POINT PARKWAY, 9TH FLOOR BRISBANE CA 94005 |
Curran Terrie | director | C/O MYOVANT SCIENCES INC. 320 WEST 37TH STREET, 5TH FLOOR NEW YORK NY 10018 |
Gulfo Adele M. | director | ONE NEENAH CENTER, 4TH FLOOR P.O. BOX 669 NEENAH WI 54957 |
Sebelius Kathleen | director | C/O DERMIRA, INC. 275 MIDDLEFIELD ROAD, SUITE 150 MENLO PARK CA 94025 |
Lang Matthew | officer: General Counsel & Corp. Secy. | C/O MYOVANT SCIENCES INC. 2000 SIERRA POINT PARKWAY, 9TH FLOOR BRISBANE CA 94005 |
Sumitomo Chemical Co., Ltd. | 10 percent owner | 27-1, SHINKAWA 2-CHOME CHUO-KU TOKYO M0 104-8260 |
Sumitovant Biopharma Ltd. | 10 percent owner | C/O ROIVANT SCIENCES, INC. 320 WEST 37TH STREET, 5TH FLOOR NEW YORK NY 10018 |
Dainippon Sumitomo Pharma Co Ltd | 10 percent owner | 60 WALL STREET NEW YORK NY 10005 |
Seely Lynn | director, officer: Principal Executive Officer | 501 2ND STREET SUITE 211 SAN FRANCISCO CA 94107 |
Sablich Kim | officer: Chief Commercial Officer | C/O MYOVANT SCIENCES INC. 2000 SIERRA POINT PARKWAY BRISBANE CA 94005 |
Nomura Hiroshi | director | C/O MYOVANT SCIENCES INC. 2000 SIERRA POINT PARKWAY BRISBANE CA 94005 |
Roivant Sciences Ltd. | 10 percent owner | CLARENDON HOUSE 2 CHURCH STREET HAMILTON D0 HM11 |
Torti Frank | director | 2855 SAND HILL ROAD MENLO PARK CA 94025 |
Other Sources
By Fool 2020-12-28
By Seekingalpha 2021-02-11
By Zacks 2021-04-13
By Zacks 2022-01-26
By Zacks 2020-12-16
By Seekingalpha 2021-06-02
By Zacks 2021-10-29
By Zacks 2020-12-29
By Zacks 2021-03-25
By Zacks 2021-05-10
By Zacks 2021-07-28
By Zacks 2021-07-01
By Zacks 2021-09-10
By Fool 2021-07-28